| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 05/12/2004 | CN1495198A Analogs of glucagon-like peptide-1 |
| 05/12/2004 | CN1495184A Substituted purine derivative, its preparation method, application and composition containing it |
| 05/12/2004 | CN1495172A Irreversible inhibitor of tyrosine kinase |
| 05/12/2004 | CN1495171A Indazol compound for inhibiting protein kinase and medicine composition and their application |
| 05/12/2004 | CN1495170A Substituted pyrazolyl benzsulfamide compound for curing inflammation |
| 05/12/2004 | CN1495169A Pyridine-3-carboxylic acid derivative |
| 05/12/2004 | CN1495166A Organic acid salt of amlodipine |
| 05/12/2004 | CN1495165A Indane or indoline derivative |
| 05/12/2004 | CN1495163A Novol pyrrole sulphamide compound |
| 05/12/2004 | CN1494920A Soft capsule preparation containing cyclosporin |
| 05/12/2004 | CN1494917A Lotion for curing hemorrhoid |
| 05/12/2004 | CN1494916A Chinese medicine composition for promoting bllod circulation and its preparation method |
| 05/12/2004 | CN1494913A Application of polygonatum polyscaccharide |
| 05/12/2004 | CN1149215C Phenyl Yanthine derivatives |
| 05/12/2004 | CN1149212C Peperidine derivatives as reuptake inhibitors |
| 05/12/2004 | CN1149210C Thrombin inhibitors |
| 05/12/2004 | CN1149209C Triazole compounds with dopamine-D3-receptor affinity |
| 05/12/2004 | CN1149204C 1-heterocycle substd. diarylamines |
| 05/12/2004 | CN1149196C Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
| 05/12/2004 | CN1149191C Azetidine derivatives, Preparation and medicines containing them |
| 05/12/2004 | CN1149095C Chinese medicine for treating baby's congenital heart disease |
| 05/12/2004 | CN1149087C Endothelin antagonist and beta receptor blocking agent as comblined preparation |
| 05/12/2004 | CN1149083C Pharmaceutical compositions containing irbesartan |
| 05/12/2004 | CN1149082C Di-and trivalent small molecule selecting protein inhibitors |
| 05/12/2004 | CN1149077C Rapidly disintegrable solid preparation |
| 05/12/2004 | CN1149018C Method and equipment for destructive distillation of haw kernel to extract juice |
| 05/11/2004 | US6734301 2,3,4,5-Tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds |
| 05/11/2004 | US6734300 Purification using cationic ion exchange resins |
| 05/11/2004 | US6734205 Substituted guanidine derivatives |
| 05/11/2004 | US6734194 Method of use of (imidazol-5-yl)methyl-2-quinolinone derivatives to inhibit smooth muscle cell proliferation |
| 05/11/2004 | US6734186 Phosphodiesterase 2 inhibitor |
| 05/11/2004 | US6734184 Arylpiperazines and their use as metalloproteinase inhibiting agents (MMP) |
| 05/11/2004 | US6734183 Useful as metalloproteinase inhibitor; piperazino-sulfonamide or piperidino-sulfonamide compound |
| 05/11/2004 | US6734179 Sulfur compounds such as 4-fluoro-n-(4-methoxy-7-(tetrahydro-pyran-4-yl)-benzothiazol-2-yl) -benzamide, used as preferential adenosine receptor ligands for the prophylaxis of neurodegenerative disorders |
| 05/11/2004 | US6734175 Administering to an obese patient or one at risk of becoming obese a therapeutic compound that attenuates the binding of agouti-related protein to melanocortin receptors, free of binding of alpha-melanocyte stimulating hormone to receptor |
| 05/11/2004 | US6734169 Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| 05/11/2004 | US6734167 Uses of transport proteins |
| 05/11/2004 | US6733994 Highly expressible genes |
| 05/11/2004 | US6733981 Antibodies to interleukin-1 β converting enzyme like apoptosis protease-3 and 4 |
| 05/11/2004 | US6733978 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 05/11/2004 | US6733801 Method of using fermented glycine max (L) extract for enhancing natural killer cell activity |
| 05/11/2004 | US6733775 Plastic films, especially for use in a dermal or transdermal therapeutic system |
| 05/11/2004 | US6733755 Ligand for vascular endothelial growth factor receptor |
| 05/11/2004 | CA2284482C Treatment of cardiomyopathy |
| 05/11/2004 | CA2156481C 5-ht2 receptor antagonist compositions useful in treating venous conditions |
| 05/11/2004 | CA2104594C Use of pharmaceutical compounds in the treatment of symptoms of disorders related to neurological diseases and etiologically related symptomology |
| 05/06/2004 | WO2004038408A2 Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 14 (gpr14) |
| 05/06/2004 | WO2004038407A2 Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 12 (gpr12) |
| 05/06/2004 | WO2004038406A2 Diagnostics and therapeutics for diseases associated with human g protein-coupled receptor 42 (gpr42) |
| 05/06/2004 | WO2004038405A2 Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 43 (gpr43) |
| 05/06/2004 | WO2004037863A1 Antibody and utilization of the same |
| 05/06/2004 | WO2004037829A1 Novel benzoxazole or oxazolopyridine compounds, method for preparing same and pharmaceutical compositions containing same |
| 05/06/2004 | WO2004037809A1 Triazole compounds for the treatment of dysmenorrhoea |
| 05/06/2004 | WO2004037806A1 N-benzodioxolyl, n-benzodioxanyl and n-benzodioxepinyl arylcarbonxamide derivatives, and pharmaceutical compositions comprising them |
| 05/06/2004 | WO2004037791A1 Inhibitors of glycogen synthase kinase 3 |
| 05/06/2004 | WO2004037778A1 Substituted tetralins and indanes |
| 05/06/2004 | WO2004037777A1 Treating syndrome x with substituted tetralins and indanes |
| 05/06/2004 | WO2004037776A2 Novel compounds and their use as prar-modulators |
| 05/06/2004 | WO2004037295A1 Method and agent for treating vulnerable plaque |
| 05/06/2004 | WO2004037290A1 Sustained release composition for oral administration of drugs |
| 05/06/2004 | WO2004037280A1 Angiogenesis inducer |
| 05/06/2004 | WO2004037276A1 Method and composition for enhancing vascular function |
| 05/06/2004 | WO2004037261A1 Use of n-‘5-‘4-(4-methylpiperaziomethyl)-benzoylamido!-2-methylphenyl!-4-(3-pyridyl)2-pyridine-amine for the treatment of pulmonary hypertension |
| 05/06/2004 | WO2004037251A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 and type 2 |
| 05/06/2004 | WO2004037233A2 Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases |
| 05/06/2004 | WO2004037184A2 Methods for the treatment of skin disorders |
| 05/06/2004 | WO2004037173A2 Method for treating erectile dysfunction and increasing libido in men |
| 05/06/2004 | WO2004018044A3 N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-'1,3,4-oxadiazol-2-yl!phenyl)pyridine-3 sulphonamide as an anticancer agent |
| 05/06/2004 | WO2004013119B1 The 9, 11-cycloendoperoxide pro-drugs of prostaglandin analogues for treatment of ocular hypertension and glaucoma |
| 05/06/2004 | WO2004011423A3 Structural carotenoid analogs for the inhibition and amelioration of disease |
| 05/06/2004 | WO2004011018A3 Methods of identifying selective beta-1-adrenergic receptor antagonists |
| 05/06/2004 | WO2004009585A3 Acyloxypyrrolidine derivatives and use thereof as ligands of v1b or both v1b and v1a receptors |
| 05/06/2004 | WO2004004750A3 Use of alanyl-aminopeptidase inhibitors and pharmaceutical compositions containing said inhibitors |
| 05/06/2004 | WO2004001002A3 Novel anticholesterol compositions and method for using same |
| 05/06/2004 | WO2004000042A3 Method and composition for treating or preventing catabolism or stimulating anabolism in a mammal undergoing metabolic stress |
| 05/06/2004 | WO2003106428A8 Arylsulphonamide derivatives and use thereof as b1 bradykinin receptor antagonists |
| 05/06/2004 | WO2003106416A3 Chemical process |
| 05/06/2004 | WO2003105893A3 Probiotic therapies using lactobacillus reuteri |
| 05/06/2004 | WO2003105838A3 MODULATION OF ACTIVATION OF GLUCOCORTICOID RECEPTORS beta-BREAKDOWN PRODUCTS OF GLUCOCORTICOIDS |
| 05/06/2004 | WO2003105779A3 Guanidine compounds as anesthetics and for treatment of nervous system disorders |
| 05/06/2004 | WO2003104254A3 Novel derivatives of androstane and androstene with ascorbic a cid and use thereof in treating or preventing various conditions, diseases, and disorders |
| 05/06/2004 | WO2003092580A3 Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor |
| 05/06/2004 | WO2003090695A3 TREATMENT OF α-GALACTOSIDASE A DEFICIENCY |
| 05/06/2004 | WO2003082853A8 New compounds |
| 05/06/2004 | WO2003016351B1 N - cam related compounds modulating cell groth |
| 05/06/2004 | WO2003010314A3 Gmg-2 polynucleotides and polypeptides and uses thereof |
| 05/06/2004 | WO2003005971A8 Tetracycline compounds having target therapeutic activities |
| 05/06/2004 | WO2003004467A3 Thiazole benzamide derivatives and pharmaceutical compositions for inhibiting cell proliferation, and methods for their use |
| 05/06/2004 | WO2002102800A9 5-(2-aminopyrimidin-4-yl) benzisoxazoles as protein kinase inhibitors |
| 05/06/2004 | WO2002089800A3 N-aroyl cyclic amine derivatives as orexin receptor antagonists |
| 05/06/2004 | WO2002088078A3 INHIBITORS OF GSK-3 AND CRYSTAL STRUCTURES OF GSK-3β PROTEIN AND PROTEIN COMPLEXES |
| 05/06/2004 | WO2002057222A9 Thiol-based naaladase inhibitors |
| 05/06/2004 | WO2002038108A3 Methods of treating disorders related to apoe |
| 05/06/2004 | WO2002020512A9 Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation |
| 05/06/2004 | US20040087801 Renin inhibitors; congesitive heart failure; glaucoma |
| 05/06/2004 | US20040087796 Substituted carbazoles as inhibitors of spla2 |
| 05/06/2004 | US20040087791 Bis(substituted propynyl)-substituted benzenes, pyridines, pyrimidines, pyrazines, pyridines, furans and pyrroles; e.g., 3,5-bis-(3-(4-aminomethylbenzylaminocarbonyloxy)prop-1-ynyl)--1 -hydroxymethylbenzene |
| 05/06/2004 | US20040087654 Nitric oxide synthase inhibitor phosphate salt |
| 05/06/2004 | US20040087646 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses |
| 05/06/2004 | US20040087645 Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events |